Business & startups

Nanopath raises US$25m to bring rapid vaginitis test to market

By Published On: November 17, 2026
Nanopath raises US$25m to bring rapid vaginitis test to market

A Massachusetts biotechnology company focused on women’s health has raised US$25m (£19m) in a Series B funding round, as it prepares to launch a rapid diagnostic test for vaginitis.

Nanopath said US$2m of the total came from non-dilutive grant funding, meaning the money does not require the company to give up equity.

The round was co-led by Norwest and the MedTech Convergence Fund, an SV Health Investors venture fund, with strategic backing from the Labcorp Venture Fund. Elderberry Ventures, GingerBread Capital and Alumni Ventures, a mix of new and existing investors, also took part.

Catherine Kiani, managing partner at Elderberry Ventures, and Mindy Nye, vice-president of Labcorp Diagnostics, have joined Nanopath’s board of observers.

The company is developing a diagnostic platform built on plasmonic biosensing, a technique that tracks changes in how light interacts with tiny metal structures when a target molecule attaches to a sensor.

Nanopath says the optical approach can detect genetic material without the amplification step used in polymerase chain reaction (PCR) testing.

Alison Burklund, Nanopath’s cofounder and co-chief executive, said the company had spent years “pressure-testing” a fundamentally new approach to molecular diagnostics “for patients who have been overlooked for far too long”.

“This funding brings us closer to the next and most important step – translating that innovation into meaningful clinical impact,” she said.

The money will go towards the commercial launch of the firm’s 15-minute point-of-care vaginitis test, including manufacturing and the start of a clinical study needed for US Food and Drug Administration (FDA) 510(k) clearance. Nanopath also intends to hire more staff across its clinical and commercial teams.

The fundraising follows a run of milestones for the company.

Last year it received the FDA’s Breakthrough Device designation for a rapid assay designed to detect infection in patients with suspected, or at risk of, complicated urinary tract infections.

A year earlier, Nanopath was awarded $4m in grants, $3m from the National Institutes of Health and $1m from the National Science Foundation, to support research and development of its platform.

It closed a US$10m Series A round in 2022, co-led by Norwest Venture Partners and the MedTech Convergence Fund, with participation from Gingerbread Capital and Green D Ventures.

Flo Health achieves medical device quality certification
Femtech launches and developments roundup